FocalTherics (NASDAQ:FOCL) Short Interest Update

FocalTherics (NASDAQ:FOCL) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 134,939 shares, a growth of 140.7% from the May 31st total of 56,059 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average daily volume of 40,322 shares, the days-to-cover ratio is currently 3.3 days.

FocalTherics Price Performance

FOCL stock remained flat at $5.18 during midday trading on Wednesday. 4,365 shares of the company traded hands, compared to its average volume of 52,486. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79. The firm has a market capitalization of $194.15 million and a price-to-earnings ratio of -6.39. FocalTherics has a 1-year low of $1.21 and a 1-year high of $5.24.

FocalTherics (NASDAQ:FOCL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $20.48 million for the quarter, compared to analyst estimates of $19.46 million. FocalTherics had a negative return on equity of 137.61% and a negative net margin of 41.47%. Research analysts expect that FocalTherics will post -0.78 earnings per share for the current year.

Insider Activity at FocalTherics

In other FocalTherics news, Director Joshua Levine purchased 10,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was purchased at an average cost of $4.22 per share, for a total transaction of $42,200.00. Following the transaction, the director owned 35,000 shares in the company, valued at $147,700. The trade was a 40.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 10.10% of the company’s stock.

Hedge Funds Weigh In On FocalTherics

Institutional investors have recently modified their holdings of the company. Flax Pond Capital LLC bought a new position in shares of FocalTherics in the fourth quarter valued at $2,623,000. Leonteq Securities AG purchased a new stake in FocalTherics in the 4th quarter valued at about $313,000. Rock Springs Capital Management LP increased its stake in FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after buying an additional 91,500 shares during the last quarter. Kovack Advisors Inc. bought a new stake in FocalTherics during the fourth quarter worth $53,000. Finally, Lido Advisors LLC bought a new stake in shares of FocalTherics during the 1st quarter worth $40,000. 62.74% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on FOCL. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a research note on Tuesday, June 2nd. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $6.00.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.